Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

2.33
-0.5700-19.66%
Pre-market: 2.330.00000.00%08:38 EDT
Volume:8.15M
Turnover:18.48M
Market Cap:194.34M
PE:-1.66
High:2.41
Open:2.38
Low:2.12
Close:2.90
52wk High:5.55
52wk Low:1.03
Shares:83.41M
Float Shares:49.56M
Volume Ratio:15.51
T/O Rate:16.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4029
EPS(LYR):-1.2813
ROE:-179.10%
ROA:-62.95%
PB:16.99
PE(LYR):-1.82

Loading ...

Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)

TIPRANKS
·
May 14

Pyxis Oncology Q1 EPS $(0.37), Inline

Benzinga Earnings
·
May 14

Pyxis Oncology Q1 Net Income USD -23.272 Million

Reuters
·
May 14

Pyxis Oncology Q1 net loss widens on higher clinical trial costs

Reuters
·
May 14

Pyxis Oncology Q1 Income From Operations USD -24.36 Million

THOMSON REUTERS
·
May 14

Pyxis Oncology Q1 EPS USD -0.37

THOMSON REUTERS
·
May 14

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances Micvo Toward Key 2026 Clinical Milestones

THOMSON REUTERS
·
May 14

Press Release: Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Dow Jones
·
May 14

Pyxis Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

Creative Global Technology Holdings And 2 Other Promising Penny Stocks

Simply Wall St.
·
May 12

Pyxis Oncology Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 11

Pyxis Oncology appoints Nelson Azoulay chief business officer

Reuters
·
May 08

Pyxis Oncology Initiated at Outperform by Wedbush

Dow Jones
·
May 05

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

TIPRANKS
·
May 05

Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target

MT Newswires Live
·
May 05

Pyxis Oncology Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $6

THOMSON REUTERS
·
May 05

Pyxis Oncology announces annual shareholder meeting notice

Reuters
·
Apr 30

Pyxis Oncology amends 8-K to disclose CEO Lara Sullivan separation agreement

Reuters
·
Apr 30

Pyxis Oncology presents new MICVO preclinical combo data supporting ongoing pembrolizumab trial

Reuters
·
Apr 18

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

GlobeNewswire
·
Apr 18